Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.
References
1.
Bataller A, Bazinet A, DiNardo C, Maiti A, Borthakur G, Daver N
. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2023; 8(4):927-935.
PMC: 10877112.
DOI: 10.1182/bloodadvances.2023011757.
View
2.
Marconi G, Candoni A, Di Nicola R, Sartor C, Parisi S, Abbenante M
. The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study. Cancer Med. 2023; 12(10):11838-11848.
PMC: 10242854.
DOI: 10.1002/cam4.5858.
View
3.
Sorror M, Storer B, Fathi A, Gerds A, Medeiros B, Shami P
. Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA Oncol. 2017; 3(12):1675-1682.
PMC: 5824273.
DOI: 10.1001/jamaoncol.2017.2714.
View
4.
Ferrara F, Barosi G, Venditti A, Angelucci E, Gobbi M, Pane F
. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013; 27(5):997-9.
DOI: 10.1038/leu.2012.303.
View
5.
Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C
. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia. Cancer. 2023; 129(7):992-1004.
DOI: 10.1002/cncr.34608.
View